Praziquantel

Revision as of 15:46, 26 December 2014 by Deepika Beereddy (talk | contribs)
Jump to navigation Jump to search

Praziquantel
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Praziquantel is an anthelmintic, antiparasitic agent that is FDA approved for the treatment of clonorchiasis, infection by opisthorchis viverrini, schistosomiasis. Common adverse reactions include cardiac dysrhythmia, rash, urticaria, abdominal pain, defecation urgency, diarrhea, hemorrhagic diarrhea, nausea, vomiting, dizziness, headache, acute CNS inflammatory disease, seizure, somnolence, fever, malaise.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Clonorchiasis
  • Dosing Information
  • The recommended dose for clonorchiasis or opisthorchiasis is 25 milligrams/kilogram/day 3 times a day as a 1-day treatment. The interval between doses should be not less than 4 and not more than 6 hours. The tablets should be taken with meals and washed down with water.
Infection by Opisthorchis viverrini
  • Dosing Information
  • The recommended dose for clonorchiasis or opisthorchiasis is 25 milligrams/kilogram 3 times a day as a 1-day treatment. The interval between doses should be not less than 4 and not more than 6 hours. The tablets should be taken with meals and washed down with water.
Schistosomiasis
  • Dosing Information
  • The recommended adult dose for Schistosoma hematobium, Schistosoma japonicum, Schistosoma mansoni, and Schistosoma mekongi is praziquantel 20 milligrams/kilogram 3 times a day as a 1-day treatment. The interval between the individual doses should not be less than 4 and not more than 6 hours.
  • Praziquantel tablets should be swallowed whole (unchewed) and washed down with water during meals. If the tablets or parts of the tablets are kept in the mouth, a bitter taste (which can promote gagging or vomiting) may be experienced.
  • Although single dose therapy is effective, the administration of larger doses has been reported in some studies to be associated with a higher incidence of adverse effects than seen with repeated smaller doses.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Praziquantel in adult patients.

Non–Guideline-Supported Use

  • Infection by Paragonimus

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Clonorchiasis

  • Dosing Information
  • Safety of praziquantel in children under 4 years of age has not been established.
  • The recommended dose for clonorchiasis or opisthorchiasis is 25 milligrams/kilogram 3 times a day as a 1-day treatment. The interval between the individual doses should not be less than 4 hours and not more than 6 hours.
  • Praziquantel tablets should be swallowed whole (unchewed) and washed down with water during meals. If the tablets or parts of the tablets are kept in the mouth, a bitter taste (which can promote gagging or vomiting) may be experienced.
Infection by Opisthorchis viverrini
  • Dosing Information
  • Safety of praziquantel in children under 4 years of age has not been established.
  • The recommended dose for clonorchiasis or opisthorchiasis is 25 milligrams/kilogram 3 times a day as a 1-day treatment. The interval between the individual doses should not be less than 4 hours and not more than 6 hours.
  • Praziquantel tablets should be swallowed whole (unchewed) and washed down with water during meals. If the tablets or parts of the tablets are kept in the mouth, a bitter taste (which can promote gagging or vomiting) may be experienced.

Schistosomiasis

  • Dosing Information
  • Safety of praziquantel in children under 4 years of age has not been established.
  • The recommended dose for Schistosoma infections in children 4 years of age or older is praziquantel 20 milligrams/kilogram 3 times a day as a 1-day treatment. The interval between the individual doses should not be less than 4 hours and not more than 6 hours.
  • Praziquantel tablets should be swallowed whole (unchewed) and washed down with water during meals. If the tablets or parts of the tablets are kept in the mouth, a bitter taste (which can promote gagging or vomiting) may be experienced.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Praziquantel in pediatric patients.

Non–Guideline-Supported Use

Hymenolepiasis
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Praziquantel in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

  • There is limited information regarding Clinical Trial Experience of Praziquantel in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

  • There is limited information regarding Postmarketing Experience of Praziquantel in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category
  • There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Praziquantel in women who are pregnant.

Labor and Delivery

  • There is no FDA guidance on use of Praziquantel during labor and delivery.

Nursing Mothers

  • There is no FDA guidance on the use of Praziquantel with respect to nursing mothers.

Pediatric Use

  • There is no FDA guidance on the use of Praziquantel with respect to pediatric patients.

Geriatic Use

  • There is no FDA guidance on the use of Praziquantel with respect to geriatric patients.

Gender

  • There is no FDA guidance on the use of Praziquantel with respect to specific gender populations.

Race

  • There is no FDA guidance on the use of Praziquantel with respect to specific racial populations.

Renal Impairment

  • There is no FDA guidance on the use of Praziquantel in patients with renal impairment.

Hepatic Impairment

  • There is no FDA guidance on the use of Praziquantel in patients with hepatic impairment.

Females of Reproductive Potential and Males

  • There is no FDA guidance on the use of Praziquantel in women of reproductive potentials and males.

Immunocompromised Patients

  • There is no FDA guidance one the use of Praziquantel in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Praziquantel in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Praziquantel in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Praziquantel in the drug label.

Pharmacology

There is limited information regarding Praziquantel Pharmacology in the drug label.

Mechanism of Action

Structure

File:Praziquantel01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Praziquantel in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Praziquantel in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Praziquantel in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Praziquantel in the drug label.

How Supplied

Storage

There is limited information regarding Praziquantel Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Praziquantel |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Praziquantel |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Praziquantel in the drug label.

Precautions with Alcohol

  • Alcohol-Praziquantel interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Praziquantel
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Praziquantel
 |Label Name=Praziquantel11.png

}}

{{#subobject: 

 |Label Page=Praziquantel
 |Label Name=Praziquantel11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Praziquantel&oldid=1050700"